PolTREG S.A. (PTG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PolTREG S.A. (PTG) has a cash flow conversion efficiency ratio of -0.154x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-7.63 Million ≈ $-2.10 Million USD) by net assets (zł49.48 Million ≈ $13.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PolTREG S.A. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how PolTREG S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PTG current and long-term liabilities for a breakdown of total debt and financial obligations.
PolTREG S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PolTREG S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TMK Energy Ltd
AU:TMK
|
-0.030x |
|
Calgro M3 Holdings Ltd
JSE:CGR
|
-0.059x |
|
Kidoz Inc
V:KIDZ
|
0.061x |
|
Leyand International Tbk
JK:LAPD
|
0.140x |
|
Termorex
WAR:TRR
|
-0.117x |
|
JPEL Private Equity Ltd
LSE:JPEL
|
0.022x |
|
Aneka Jaringan Holdings Bhd
KLSE:0226
|
-0.080x |
|
Murudeshwar Ceramics Limited
NSE:MURUDCERA
|
0.023x |
Annual Cash Flow Conversion Efficiency for PolTREG S.A. (2018–2024)
The table below shows the annual cash flow conversion efficiency of PolTREG S.A. from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see PTG market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł69.23 Million ≈ $19.05 Million |
zł-16.00 Million ≈ $-4.40 Million |
-0.231x | -52.30% |
| 2023-12-31 | zł87.52 Million ≈ $24.09 Million |
zł-13.28 Million ≈ $-3.66 Million |
-0.152x | -78.29% |
| 2022-12-31 | zł101.04 Million ≈ $27.81 Million |
zł-8.60 Million ≈ $-2.37 Million |
-0.085x | -128.55% |
| 2021-12-31 | zł103.01 Million ≈ $28.35 Million |
zł-3.84 Million ≈ $-1.06 Million |
-0.037x | +82.85% |
| 2020-12-31 | zł12.83 Million ≈ $3.53 Million |
zł-2.79 Million ≈ $-767.30K |
-0.217x | -100.11% |
| 2019-12-31 | zł-6.00K ≈ $-1.65K |
zł-1.19 Million ≈ $-327.51K |
198.333x | +14627.96% |
| 2018-12-31 | zł764.00K ≈ $210.26K |
zł-1.04 Million ≈ $-287.05K |
-1.365x | -- |
About PolTREG S.A.
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland.